Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study
Patients with metastatic prostate cancer initially respond to androgen deprivation therapy (ADT), often combined with docetaxel or an androgen receptor pathway inhibitor (ARPI); however, many eventually progress to metastatic castration‑resistant prostate cancer (mCRPC).
The majority of prostate cancer patients survive years after diagnosis, but a subset develops aggressive, treatment‑resistant neuroendocrine variants that rapidly progress and have limited therapeutic options.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience